Levetiracetam Injection, Solution, Concentrate
Product Images NDC 67457-790

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 67457-790). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Institutional Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Image 01)

Chemical structure diagram of levetiracetam, showing its molecular bonds and layout including a pyrrolidone ring attached to an ethyl side chain and an amide group.*

FDA Label Image

Figure 1 (Image 02)

Bar graph showing responder rates (≥50% reduction from baseline) in Study 1 comparing placebo and levetiracetam at daily doses of 1000 mg and 3000 mg. The y-axis represents the percentage of patients, with placebo at 7.4%, levetiracetam 1000 mg/day at 37.1%, and levetiracetam 3000 mg/day at 39.6%. Both levetiracetam groups show statistically significant improvements versus placebo.*

FDA Label Image

Figure 2 (Image 03)

A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A' showing the percentage of patients responding to treatment. It compares placebo (6.3%), levetiracetam 1000 mg/day (20.8%), and levetiracetam 2000 mg/day (35.2%). The chart indicates statistical significance of levetiracetam groups versus placebo.*

FDA Label Image

Figure 5 (Image 04)

A bar chart showing responder rates (≥ 50% reduction from baseline) in Study 4. The y-axis represents percentage of patients from 0% to 45%. Two bars compare placebo (19.6%, N=97) and levetiracetam (44.6%, N=101), with levetiracetam showing a higher responder rate.*

FDA Label Image

Figure 5 (Image 05)

Bar graph titled 'Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5' depicting percentage of patients responding in two groups: Placebo (N=51) with 19.6% responders and Levetiracetam (N=58) with 43.1% responders. An asterisk denotes statistical significance versus placebo.*

FDA Label Image

Figure 6 (Image 06)

Bar chart showing the responder rate (≥50% reduction from baseline) in partial generalized tonic-clonic (PGTC) seizure frequency per week in Study 7. The chart compares Placebo (N=84) with 45.2% responders and Levetiracetam (N=79) with 72.2% responders, indicating a statistically significant difference favoring Levetiracetam.*

FDA Label Image

Figure 3 (Image 07)

Bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 3' depicting the percentage of patients responding to treatment. One bar shows 14.4% responders in the placebo group (N=104), and the other shows 39.4% responders at levetiracetam 3000 mg/day (N=180), with an asterisk indicating statistical significance versus placebo.*

FDA Label Image

Carton.jpg (Image 12)

Packaging label for levetiracetam injection USP 500 mg/5 mL (100 mg/mL) by Mylan Institutional LLC. The label specifies intravenous use only, requiring dilution prior to administration, with packaging containing 10 single-dose 5 mL vials. It includes storage instructions and manufacturer details, noting the product is sterile and Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.